AASLD 2016 Archives - MPR

AASLD 2016

SOF/VEL/VOX Effective as Retreatment for Non-NS5A DAA Failures

Treatment with single tablet sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for 12 weeks “is a highly effective salvage therapy” for patients who did not previously achieve sustained virologic response (SVR) following treatment with non-NS5A inhibitor-containing direct-acting antivirals (DAAs), results from the POLARIS-4 study presented at The Liver Meeting® 2016 have shown.